Meta-Analysis of Alterations in Regulatory T Cells’ Frequency and Suppressive Capacity in Patients with Vitiligo

Figure 5

The forest plots for Tregs’ frequency, FOXP3, and IL-10 levels in vitiligo pre- and posttreatment. (a) Tregs’ frequency posttreatment vs. pretreatment (, SMD: 1.64 [0.45, 2.83]). Tregs’ frequency posttreatment vs. pretreatment in mouse models of vitiligo (, SMD: 2.11 [0.43, 3.78]). Tregs’ frequency post treatment vs. pretreatment in human studies for vitiligo ( SMD: 1.16 [-0.65, 2.96]). (b) FOXP3 protein levels posttreatment vs. pretreatment (, SMD: 3.43 [1.90, 4.96]). FOXP3 protein levels posttreatment vs. pretreatment in vitiligo mice model study (, SMD: 3.43 [1.44, 5.43]). FOXP3 protein levels posttreatment vs. pretreatment in human studies (, 3.34 [1.13, 5.54]). (c) IL-10 levels posttreatment vs. pretreatment in vitiligo patients (, SMD: 1.32 [0.47, 2.17]). IL-10 levels posttreatments vs. pretreatment in vitiligo mice models study (, SMD: 2.98 [1.37, 4.59]). IL-10 levels post treatment vs. pretreatment in vitiligo human studies (, 0.82 [0.35, 1.29]).

(a)

(b)

(c)